BMS joins forces with insitro to develop neurodegenerative treatmentsinsitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies Share XBMS joins forces with insitro to develop neurodegenerative treatmentshttps://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/
Roger Perlmutter leaves Merck after 7 years, joins board at InsitroRoger Perlmutter has brought a seven-year stint as head of R&D at Merck & Co/MSD to a close, Share XRoger Perlmutter leaves Merck after 7 years, joins board at Insitrohttps://pharmaphorum.com/news/roger-perlmutter-leaves-merck-after-7-years-joins-board-at-insitro/
AI firm Insitro signs Gilead as first pharma partner with NASH dealLess than a year after coming out of stealth mode with a $65 million first-round last year, artificial Share XAI firm Insitro signs Gilead as first pharma partner with NASH dealhttps://pharmaphorum.com/digital/ai-insitro-gilead-pharma-partner/
